Organon & Co. (OGN) Competitors

Organon & Co. (NYSE:OGN) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Is OGN or ASND more profitable?

Organon & Co. has a net margin of 11.15% compared to Ascendis Pharma A/S's net margin of -93.22%. Organon & Co.'s return on equity of 182.69% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	11.15%	182.69%	7.06%
Ascendis Pharma A/S	-93.22%	N/A	-33.29%

Which has more risk and volatility, OGN or ASND?

Organon & Co. has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500.

Does the media refer more to OGN or ASND?

In the previous week, Organon & Co. had 12 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 21 mentions for Organon & Co. and 9 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.64 beat Organon & Co.'s score of 0.40 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	4 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders believe in OGN or ASND?

77.4% of Organon & Co. shares are held by institutional investors. 2.0% of Organon & Co. shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Do analysts recommend OGN or ASND?

Organon & Co. presently has a consensus price target of $18.00, indicating a potential upside of 97.69%. Ascendis Pharma A/S has a consensus price target of $223.67, indicating a potential upside of 17.50%. Given Organon & Co.'s higher possible upside, analysts clearly believe Organon & Co. is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Ascendis Pharma A/S	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has preferable valuation and earnings, OGN or ASND?

Organon & Co. has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.40B	0.37	$864M	$2.69	3.38
Ascendis Pharma A/S	$393.54M	29.58	-$409.12M	-$6.28	-30.31

Summary

Organon & Co. beats Ascendis Pharma A/S on 12 of the 17 factors compared between the two stocks.